Indeed, we found that both eosinophilia and eosinophil activation, as well as circulating IL-5 levels, increased during treatment and dropped to below baseline six months thereafter, in line with several treatment studies in endemic [26,57,58] and non-endemic [59] populations. This evidence concerns the gene IL5 and Increased total eosinophil count.